Half and half Pathways: Assorted qualities and Union in Toronto's Life Science Advancement Framework.

Uploaded on:
Category: Medical / Health
Meric S. Gertler and Nichola J. Lowe Program on Globalization and Local Advancement Frameworks Community for Worldwide Studies College of Toronto Presentation to the 6 th Yearly ISRN Meeting Wosk Place for Dialog Simon Fraser College, Vancouver May 13-14, 2004.
Slide 1

Meric S. Gertler and Nichola J. Lowe Program on Globalization and Regional Innovation Systems Center for International Studies University of Toronto Presentation to the 6 th Annual ISRN Meeting Wosk Center for Dialog Simon Fraser University, Vancouver May 13-14, 2004 Hybrid Pathways: Diversity & Convergence in Toronto’s Life Science Innovation System

Slide 2

Toronto’s Life Science Cluster: Mixed Messages ICF study: one of biggest life science bunches in North America ‘Profile problem’ ‘hidden’ inside of a huge, various economy No prominent, expansive, home-developed devoted biotech ‘star firms’ GTA life science: profoundly assorted blend Argument: previous liabilities getting to be temperances

Slide 3

Economic estimation of differences Increases mixed bag in information pool (inside of firms, inside of city-areas), raising potential for advancement from intuitive learning Decreases hazard for individual firms (numerous exercises, qualities, wellsprings of income) Increases flexibility of RIS by and large (a more broadened portfolio; learning, versatility)

Slide 4

Regional Life Science Innovation System National, commonplace establishments shape structure for local performers , systems, arrangement activities Interaction between these distinctive sizes of administration helps shape extraordinary nearby attributes of framework, capacities of on-screen characters (firms, researchers, associations) Local abilities, qualities sustain neighborhood new businesses; additionally pull in worldwide players PSE framework underpins improvement of ability, ‘stars’; nature of spot decides maintenance, fascination

Slide 5

GTA’s Life Science Innovation System: Supply Side Knowledge generation: US-style open $$ for college research (CIHR, NSERC) But college framework ruled by open proprietorship; both government & common part US-style star researcher framework (as of late upgraded: CRCs, CFI, ORDCF, OIT, PREA) Knowledge misuse: US-style entrepreneurial arrangement of firm arrangement US-style money related framework (private VC, heavenly attendants, TSX) Regulatory environment: IP rights: no Bayh-Dole Act (loads of nearby variety) Federal part: Health Canada (drug regard); patent administration; compulsory authorizing (conception of nonexclusive medication industry)

Slide 6

GTA’s Life Science Innovation System: Demand Side Regulatory environment/acquiring: Provincial part: Ministry of Health Drug Formulary (posting, evaluating) Hospitals (brought together, decentralized) Regulatory environment: US FDA: access to US business sector is key Big pharma: Contracting out exploration (to meet R&D commitments) Contract producing

Slide 7

Greater Toronto LSIS: I. Bio/Pharma Firms Brand name (worldwide) pharma GSK, Pfizer, Aventis, Roche, Merck, Eli Lilly, Astra-Zeneca, Bayer Generic (neighborhood) pharma Apotex, Novopharm, Genpharm, ratiopharm ‘Core’ (nearby) biotechnology Large Biovail, Cangene, Draxis, Hemosol, GlycoDesign Newer new companies( (basically little) SynX, Tm Bioscience, MDS Proteomics

Slide 8

II. Biomedical Technology and Devices Firms Global producers J&J, Baxter, Medtronics, GE, Agfa Specialized (national) merchants and CMO’s SouthMedic, Canadian Hospital Specialties, MediChair Local makers Initial begin in dispersion and repair Canadian Endoscope, Baylis Medical, SciCan Manufacturing new companies Hart Mobility, Variety Ability, Tash Inc., VisuAide, Cedara Biotech-BTD, IT-BTD, Material Sci-BTD interface Pheromone Science, Interface Biologics, Delex Therapeutics, Toxin Alert, VisualSonics, Tm Bioscience

Slide 9

III. Different Firms in the Life Sciences Value Chain CROs: Biovail CR, Patheon, MDS Pharma Sciences Capital merchandise (‘platform technologies’): MDS Sciex, Visible Genetics Venture capital: MDS Capital, CMDF, RBC Technology Ventures

Slide 10

IV. Examination, Teaching Institutions U of T Faculty of Medicine, CCBR U of T @ Mississauga (M Bio) UHN (PMH, TGH, TWH), HSC, St. Mike’s Ontario Cancer Institute Sunnybrook and Women’s College Mount Sinai – Lunenfeld RI CAMH, Baycrest McMaster, York Other territorial doctor\'s facilities

Slide 11

V. Administrative, Supporting Institutions – Provincial, Local Ontario Ministry of EDT BCIP consortia (4) Ontario Bio Council MaRS Discovery District TBI, TRRA

Slide 12

Life sci basic details for main 4 CMAs (NAICS 3254, 3345, 3391, 6215)

Slide 13

Life Science VC for Selected CMAs Source: Macdonald & Associates Ltd. 2004

Slide 14

VC by Sector, Toronto CMA Source: Macdonald & Associates Ltd. 2004

Slide 15

Life Science VC Invested 1998-2003, Selected CMAs Source: Macdonald & Associates Ltd. 2004

Slide 16

Canada’s Biomedical Technology and Device Clusters Source: Health Technology Exchange

Slide 17

Dimensions of Variety in Toronto Life Science NIS/RIS: US-European mix Sectors/learning pools: biotech, brand name & non specific pharma, BTD Geographical: home developed, remote firms; ‘talent’ pool (Mosaic Index +++) Hybrid techniques (firms): Within areas (‘extension’) Between segments (‘convergence’)

Slide 18

Pathways of Hybridization Type I: Technology Extension

Slide 19

Pathways of Hybridization Type II: Technology Convergence

Slide 20

Toronto: future prospects Rise of the half breed firm? (NYT: “Is biotech losing its nerve?”) Toronto’s lead firms are half and halves: MDS ($1.8B), Biovail ($1.1B) VCs: figuring out how to love cross breeds Now effectively coordinating crossover firm improvement Toronto’s life science ‘cluster’ Path subordinate advancement in light of legacy of

View more...